Pulmonary Embolism - Pipeline Review, H2 2018

  • ID: 4604406
  • Drug Pipelines
  • 37 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Verseon Corp
  • MORE
Pulmonary Embolism - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.

Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood clot. Symptoms include shortness of breath, chest pain, cough, leg pain or swelling, excessive sweating, rapid or irregular heartbeat and dizziness. Predisposing factors include High blood pressure and cardiovascular disease. Treatment includes anticoagulants and thrombolytics.

Report Highlights:

This latest pipeline guide Pulmonary Embolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 2, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pulmonary Embolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pulmonary Embolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Verseon Corp
  • MORE
Introduction

Report Coverage

Pulmonary Embolism - Overview

Pulmonary Embolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pulmonary Embolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pulmonary Embolism - Companies Involved in Therapeutics Development

Accu-Break Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dong-A Socio Holdings Co Ltd

F. Hoffmann-La Roche Ltd

Tasly Pharmaceutical Group Co Ltd

Verseon Corp

Pulmonary Embolism - Drug Profiles

DS-1040 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heparin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urokinase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-1902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

warfarin potassium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pulmonary Embolism - Dormant Projects

Pulmonary Embolism - Discontinued Products

Pulmonary Embolism - Product Development Milestones

Featured News & Press Releases

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pulmonary Embolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals Inc, H2 2018

Pulmonary Embolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Pulmonary Embolism - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pulmonary Embolism - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Pulmonary Embolism - Pipeline by Verseon Corp, H2 2018

Pulmonary Embolism - Dormant Projects, H2 2018

Pulmonary Embolism - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Pulmonary Embolism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Accu-Break Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Dong-A Socio Holdings Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • Verseon Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll